


894 F.3d 1374
United States Court of Appeals, Federal Circuit.
ENDO PHARMACEUTICALS SOLUTIONS, INC., Bayer Intellectual Property GMBH, Bayer Pharma AG, Plaintiffs-Appellees
v.
CUSTOPHARM INC., Defendant-Appellant
2017-1719
|
Decided: July 13, 2018
Synopsis
Background: Patentees brought action against competitor, alleging that competitor's Abbreviated New Drug Application seeking to produce and market a generic testosterone undecanoate intramuscular injection infringed two testosterone replacement therapy patents. Competitor counterclaimed alleging invalidity of the patents. Following bench trial, the United States District Court for the District of Delaware, No. 1:14-cv-01422-SLR-SRF, Sue L. Robinson, J., 234 F.Supp.3d 587, determined that patents were not invalid as obvious. Competitor appealed.
 
Holdings: The Court of Appeals, Chen, Circuit Judge, held that:
 
skilled artisan would not have been motivated by prior art articles to lower dose of testosterone undecanoate, and
 
patent claims were not obvious over prior art.
 
Affirmed.
 
Procedural Posture(s): On Appeal; Judgment.
*1376 Appeal from the United States District Court for the District of Delaware in No. 1:14-cv-01422-SLR-SRF, Judge Sue L. Robinson.
